• Je něco špatně v tomto záznamu ?

Synthesis and in vitro Study of Artemisinin/Synthetic Peroxide-Based Hybrid Compounds against SARS-CoV-2 and Cancer

L. Herrmann, IA. Yaremenko, A. Çapcı, J. Struwe, D. Tailor, A. Dheeraj, J. Hodek, YY. Belyakova, PS. Radulov, J. Weber, SV. Malhotra, AO. Terent'ev, L. Ackermann, SB. Tsogoeva

. 2022 ; 17 (9) : e202200005. [pub] 20220329

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018475

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause life-threatening diseases in millions of people worldwide, in particular, in patients with cancer, and there is an urgent need for antiviral agents against this infection. While in vitro activities of artemisinins against SARS-CoV-2 and cancer have recently been demonstrated, no study of artemisinin and/or synthetic peroxide-based hybrid compounds active against both cancer and SARS-CoV-2 has been reported yet. However, the hybrid drug's properties (e. g., activity and/or selectivity) can be improved compared to its parent compounds and effective new agents can be obtained by modification/hybridization of existing drugs or bioactive natural products. In this study, a series of new artesunic acid and synthetic peroxide based new hybrids were synthesized and analyzed in vitro for the first time for their inhibitory activity against SARS-CoV-2 and leukemia cell lines. Several artesunic acid-derived hybrids exerted a similar or stronger potency against K562 leukemia cells (81-83 % inhibition values) than the reference drug doxorubicin (78 % inhibition value) and they were also more efficient than their parent compounds artesunic acid (49.2 % inhibition value) and quinoline derivative (5.5 % inhibition value). Interestingly, the same artesunic acid-quinoline hybrids also show inhibitory activity against SARS-CoV-2 in vitro (EC50 13-19 μm) and no cytotoxic effects on Vero E6 cells (CC50 up to 110 μM). These results provide a valuable basis for design of further artemisinin-derived hybrids to treat both cancer and SARS-CoV-2 infections.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018475
003      
CZ-PrNML
005      
20220804134807.0
007      
ta
008      
220720s2022 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cmdc.202200005 $2 doi
035    __
$a (PubMed)35187791
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Herrmann, Lars $u Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials (ICMM), Friedrich-Alexander-University Erlangen-Nürnberg, Nikolaus Fiebiger-Straße 10, 91058, Erlangen, Germany
245    10
$a Synthesis and in vitro Study of Artemisinin/Synthetic Peroxide-Based Hybrid Compounds against SARS-CoV-2 and Cancer / $c L. Herrmann, IA. Yaremenko, A. Çapcı, J. Struwe, D. Tailor, A. Dheeraj, J. Hodek, YY. Belyakova, PS. Radulov, J. Weber, SV. Malhotra, AO. Terent'ev, L. Ackermann, SB. Tsogoeva
520    9_
$a The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause life-threatening diseases in millions of people worldwide, in particular, in patients with cancer, and there is an urgent need for antiviral agents against this infection. While in vitro activities of artemisinins against SARS-CoV-2 and cancer have recently been demonstrated, no study of artemisinin and/or synthetic peroxide-based hybrid compounds active against both cancer and SARS-CoV-2 has been reported yet. However, the hybrid drug's properties (e. g., activity and/or selectivity) can be improved compared to its parent compounds and effective new agents can be obtained by modification/hybridization of existing drugs or bioactive natural products. In this study, a series of new artesunic acid and synthetic peroxide based new hybrids were synthesized and analyzed in vitro for the first time for their inhibitory activity against SARS-CoV-2 and leukemia cell lines. Several artesunic acid-derived hybrids exerted a similar or stronger potency against K562 leukemia cells (81-83 % inhibition values) than the reference drug doxorubicin (78 % inhibition value) and they were also more efficient than their parent compounds artesunic acid (49.2 % inhibition value) and quinoline derivative (5.5 % inhibition value). Interestingly, the same artesunic acid-quinoline hybrids also show inhibitory activity against SARS-CoV-2 in vitro (EC50 13-19 μm) and no cytotoxic effects on Vero E6 cells (CC50 up to 110 μM). These results provide a valuable basis for design of further artemisinin-derived hybrids to treat both cancer and SARS-CoV-2 infections.
650    _2
$a zvířata $7 D000818
650    _2
$a antivirové látky $x farmakologie $x terapeutické užití $7 D000998
650    12
$a artemisininy $x farmakologie $7 D037621
650    12
$a COVID-19 $7 D000086382
650    _2
$a Cercopithecus aethiops $7 D002522
650    _2
$a lidé $7 D006801
650    12
$a leukemie $x farmakoterapie $7 D007938
650    12
$a nádory $x farmakoterapie $7 D009369
650    _2
$a peroxidy $7 D010545
650    12
$a chinoliny $x terapeutické užití $7 D011804
650    _2
$a SARS-CoV-2 $7 D000086402
650    _2
$a Vero buňky $7 D014709
650    _2
$a farmakoterapie COVID-19 $7 D000093485
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Yaremenko, Ivan A $u N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky prosp., 119991, Moscow, Russian Federation $1 https://orcid.org/0000000310689051
700    1_
$a Çapcı, Aysun $u Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials (ICMM), Friedrich-Alexander-University Erlangen-Nürnberg, Nikolaus Fiebiger-Straße 10, 91058, Erlangen, Germany
700    1_
$a Struwe, Julia $u Institut für Organische und Biomolekulare Chemie, Georg-August-Universität Göttingen, Tammannstraße 2, 37077, Göttingen, Germany
700    1_
$a Tailor, Dhanir $u Department of Cell, Developmental and Cancer Biology, Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health and Science University, 97201, Portland, OR, USA
700    1_
$a Dheeraj, Arpit $u Department of Cell, Developmental and Cancer Biology, Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health and Science University, 97201, Portland, OR, USA
700    1_
$a Hodek, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo namesti 2, 16610, Prague, Czech Republic
700    1_
$a Belyakova, Yulia Yu $u N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky prosp., 119991, Moscow, Russian Federation
700    1_
$a Radulov, Peter S $u N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky prosp., 119991, Moscow, Russian Federation $1 https://orcid.org/0000000326530395
700    1_
$a Weber, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo namesti 2, 16610, Prague, Czech Republic $1 https://orcid.org/0000000227997352 $7 xx0102542
700    1_
$a Malhotra, Sanjay V $u Department of Cell, Developmental and Cancer Biology, Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health and Science University, 97201, Portland, OR, USA
700    1_
$a Terent'ev, Alexander O $u N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky prosp., 119991, Moscow, Russian Federation $1 https://orcid.org/000000018018031X
700    1_
$a Ackermann, Lutz $u Institut für Organische und Biomolekulare Chemie, Georg-August-Universität Göttingen, Tammannstraße 2, 37077, Göttingen, Germany $u German Center for Cardiovascular Research (DZHK), Potsdamer Str. 58, 10785, Berlin, Germany $1 https://orcid.org/0000000170348772
700    1_
$a Tsogoeva, Svetlana B $u Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials (ICMM), Friedrich-Alexander-University Erlangen-Nürnberg, Nikolaus Fiebiger-Straße 10, 91058, Erlangen, Germany $1 https://orcid.org/0000000348450951
773    0_
$w MED00173270 $t ChemMedChem $x 1860-7187 $g Roč. 17, č. 9 (2022), s. e202200005
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35187791 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134801 $b ABA008
999    __
$a ok $b bmc $g 1822183 $s 1169718
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 17 $c 9 $d e202200005 $e 20220329 $i 1860-7187 $m ChemMedChem $n ChemMedChem $x MED00173270
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace